Clinical trials: Post COVID Condition
COVID-19, Sars-CoV-2 Infection
Efficacy and Safety of NVX-CoV2705
This is a Phase 4, post-market US study, evaluating the efficacy and safety of a single dose of the NVX-CoV2705 Omicron JN.1 COVID-19 vaccine.
- Trial name
- COVID-19 (NCT07086222)
- Testing
- NVX-CoV2705
- Where
- 99 sites in United States
- Volunteers
- 6,500 people, healthy volunteers welcome
- Sponsor
- Novavax
SARS-CoV-2, COVID-19
Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years
The purpose of this post-marketing study is to assess the safety of Comirnaty monovalent XBB.1.5. for booster vaccination children ages 6 months though 4 years under actual use medical practice.
- Trial name
- NCT06130410
- Testing
- COMIRNATY intramuscular injection
- Where
- Japan
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers
In order to assess the efficacy of hydroxychloroquine treatment weekly for a total of 7 weeks in the prevention of COVID-19 infection, three hundred sixty (360) Healthcare workers with high risk exposure to patients infected with…
- Trial name
- NCT04333225
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- Baylor Research Institute
Post-Acute COVID-19 Syndrome, ME/CFS
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related…
- Conditions
- Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA)
- Trial name
- NCT04806620
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Brain Inflammation Collaborative
COVID-19 Pandemic
Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine
A Randomized, Double Blind, Positive Control Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18…
- Trial name
- COVID-19 (NCT05238649)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg, Recombinant SARS-CoV-2 Fusion Protein Vaccine 25μg, SARS-Cov-2 Vaccine Inactivated
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
Covid19, COVID-19 Prevention
Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19
COVID-19 affected more than 9 million of people with more than 130 thousand death in India. If adequate preventive and therapeutic measures are not taken, India has very high risk of affecting million of more people with high…
- Trial name
- PEP-CQ (NCT04858633)
- Testing
- Hydroxychloroquine (HCQ), Standard care
- Where
- India
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Covid19
Profiling Antibody Status and Vaccine Effectiveness in Post Vaccination With SARS CoV2 in Ain Shams University
This is a prospective intervention study to assess the effectiveness of both the live attenuated and messenger RNA vaccines against SARS-CoV-2 infection
- Trial name
- ASU-VAC (NCT04885764)
- Testing
- Astrazeneca/Oxford Vaccine, Sinopharm vaccine
- Where
- Egypt
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Postural Orthostatic Tachycardia Syndrome, Post Acute Sequelae of SARS CoV 2 Infection
NC Testing in LC & POTS
Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Post-Acute Sequelae of COVID (PASC, or "Long COVID") experience cognitive dysfunction.
- Trial name
- NCT05914649
- Testing
- IV normal saline (999 mL infusion), IV normal saline (50 mL infusion)
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Long COVID, Pain
Pain Relief With Integrative Medicine (PRIMe)?: Feasibility of Acupuncture for Long COVID
The goal of this preliminary study is to test methods and procedures to be used in a fully-powered trial to evaluate acupuncture treatment effectiveness.
- Trial name
- NCT06476496
- Testing
- Acupuncture
- Where
- United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- University of Washington
COVID 19, Thromboembolic and Bleeding Complications
Thromboembolic Complications in Mild Covid-19 Cases
The aim of the study is to investigate the frequency of thromboembolic complications and the factors influencing them in COVID-19 cases that did not require hospitalization.
- Conditions
- COVID 19, Thromboembolic and Bleeding Complications, Thromboembolism, Venous, Post COVID-19
- Trial name
- NCT06695377
- Where
- Turkey (Türkiye)
- Volunteers
- 961 people, healthy volunteers welcome
- Sponsor
- Marmara University Pendik Training and Research Hospital
SARS-CoV-2
Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States
The goal of this study is to add to the ongoing active and passive safety signal detection through signal refinement and, if needed, evaluation of potential safety signals related to taking the SARS-CoV-2 mRNA-1273 vaccine.
- Trial name
- NCT04958954
- Where
- United States
- Volunteers
- 50,000,000 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19
"Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Drug B10-FC After Single Administration to Adult Patients".
A two-stage open-label, prospective, safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity study with participation of healthy volunteers in three dose-escalation groups and patients with a confirmed…
- Trial name
- NCT07156864
- Testing
- 1/10 therapeutic dose, 1/2 therapeutic dose, full therapeutic dose
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
COVID-19
Impact of Long COVID-19 on the Health and Quality of Life of Military Personnel (Active or Retired) and Their Families
Severe and sometimes irreversible sequelae are observed in people who have developed a severe form of COVID-19 (pulmonary, cardiovascular, renal, neurological sequelae among others).
- Trial name
- IMP@LA (NCT05200832)
- Testing
- Online questionnaire, Semi-structured interview
- Where
- France
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Direction Centrale du Service de Santé des Armées
Post COVID Condition, Chronic Pain
Effect of Non-Invasive Neuromodulation on Primary Chronic Pain, Including Post-COVID-19
The aim of this study is to analyse whether there is an advantage in adding low-intensity electrical stimulations to the vagus nerve with electrodes in the outer ear to control pain and fatigue in people with primary chronic…
- Conditions
- Post COVID Condition, Chronic Pain, Healthy
- Trial name
- NCT06689345
- Testing
- taVNS - transauricular vagal nerve stimulation, rPMS - repetitive peripheric magnetic stimulation, rTMS - repetitive transcranial magnetic stimulation
- Where
- Brazil
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Federal University of ABC
SARS-CoV-2
Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran
The main objective of the study is to evaluate the safety of the elasomeran/davesomeran and andusomeran vaccines as used in routine clinical practice.
- Trial name
- NCT06130345
- Testing
- SPIKEVAX
- Where
- United States
- Volunteers
- 15,196,685 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Psychosis;Schizophrenic, Personality Disorders
The Impact of the COVID-19 (SARS-CoV-2 Disease) on Psychopathology
The outbreak of the SARS-CoV-2 pandemic may be considered a traumatic phenomenon. In a sample of subjects suffering from different psychiatric disorders, psychopathological status and Post-Traumatic Stress Disorder (PTSD)…
- Conditions
- Psychosis;Schizophrenic, Personality Disorders, Mood Disorders, Anxiety Disorders
- Trial name
- NCT04694482
- Testing
- Psychometric scale administration
- Where
- Italy
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- University of Milano Bicocca
COVID-19, Pain, Chronic
Pain-related Long Covid in Covid-19 Survivors
The exploratory project aims to investigate the presence of pain as a long Covid-19 symptom in previously hospitalised patients and in non-hospitalised persons previously tested positive in a PCR test.
- Trial name
- NCT05520931
- Testing
- Questionnaire and register-based data assessment
- Where
- Denmark
- Volunteers
- 600,000 people, healthy volunteers welcome
- Sponsor
- Aalborg University
Coronavirus Disease 2019
Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells)
Popular topic:Clinical trials of the consistency and non-inferiority bridging between batches of recombinant new coronavirus vaccine (CHO cells) Research purpose:Main purpose:1)To evaluate the interbatch consistency of…
- Trial name
- NCT05091411
- Testing
- Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 1,680 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Covid19
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
VXA-CoV2-1 is a non-replicating Ad5 vector adjuvanted oral tableted vaccine being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- NCT04563702
- Testing
- VXA-CoV2-1
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Vaxart
SARS-CoV-2 Infection
Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine
This study aims to address evidence gaps regarding the safety, reactogenicity and immune responses of a heterologous boost of a single dose of Ad26.COV2.S (half or full dose) at pre-specified time intervals in recipients who are…
- Trial name
- NCT05109559
- Testing
- Full dose of Ad26.COV2. 5x10^10vp, Half dose of Ad26.COV2. 2.5x10^10vp
- Where
- Thailand
- Volunteers
- 690 people, healthy volunteers welcome
- Sponsor
- Mahidol University